Health Care/Hospital
Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs
* The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformativeS$5.5 million gift towards research. * The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 ...
2025-01-11 22:15
512
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...
2025-01-11 17:07
1035
Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution
IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ -- Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material designed to combat the global plastic pollution crisis. Accompanying this launch is the release of the ...
2025-01-11 05:53
1722
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...
2025-01-11 01:30
1219
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-11 00:00
1519
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-10 22:00
1193
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...
2025-01-10 21:01
2060
Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress
Announces Major Milestones at the JPM Healthcare Conference
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in
neurotherapeutics discovery and development, has officially rebranded asXylo Bio
2025-01-10 21:00
745
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...
2025-01-10 17:00
2255
Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercializa...
2025-01-10 15:00
1132
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase1b/2 clinical trial. This achievement follows the designation of SNB-101 as...
2025-01-10 14:40
957
AXA, AXA Tianping, and PICC Strengthen Cooperation, MOU signed on "Green Action Global" project
Collaborating to Drive Expansion in Hong Kong Auto Insurance Market HONG KONG, Jan. 10, 2025 /PRNewswire/ -- On January 9, AXA Hong Kong and Macau ("AXA"), AXA Tianping P&C Insurance Co., Ltd. ("AXA Tianping"), andChina People's Property and Casualty Insurance Co., Ltd. ("PICC Property and Casual...
2025-01-10 12:07
1185
TriNetX's Founding CEO Announces Plans to Step Down
After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX's Board CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ -- TriNetX, the largest global source of real-world data, today announced thatGadi Lachman, the Company's Founder, President and CEO, will step down from his operating r...
2025-01-10 05:05
1115
In 2024, Complete Genomics expanded U.S. manufacturing and technology capabilities toward a diversified, reliable supply chain for its flexible and cost-effective NGS solutions
SAN JOSE, Calif., Jan. 9, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-...
2025-01-10 01:43
1083
United Imaging Announces Major Expansion of U.S. Manufacturing Space
The additional space will more than triple the square footage of the company's current production facility and headquarters inHouston, Texas HOUSTON, Jan. 9, 2025 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has signed on for additional ...
2025-01-10 01:00
952
Argon Medical Announces First Patient Enrollment in CLEAN-PE, a Prospective, Multicenter Study of a New Treatment for Pulmonary Embolism
PLANO, Texas, Jan. 9, 2025 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the first patient enrollment in the CLEAN-PE study. The prospective, multicenter C...
2025-01-09 23:01
1230
Goertek Unveils Next-Generation Smart Ring Reference Designs: A Leap Forward in Health Monitoring and Interactive Technology
LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Recent technological advancements in sensing, big data, cloud computing, IoT, and AI have significantly enhanced the capabilities of wearable devices in health monitoring. Goertek's latest smart ringreference designs, showcased at CES 2025, embodies these i...
2025-01-09 23:00
990
Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference
HANGZHOU, China, Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference inSan Francisco from January 13-16, 2025. HgC CEO Gary Xu and Apeloa VP George Cai will be present a...
2025-01-09 22:00
1617
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
* Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process * These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of in...
2025-01-09 16:41
1783
Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency
FRANKFURT, Germany, Jan. 9, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in diagnostics innovation, announces the launch of its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000, a transformative technology designed to deliver rapid, reliable, and cost-effective di...
2025-01-09 16:04
783
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 307 media titles]
2025-01-06 14:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 292 media titles]
2025-01-06 19:25
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
16858
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
2025-01-07 09:00
5116
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
2025-01-06 14:00
4768
CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
2025-01-06 19:25
4533
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
2025-01-06 21:00
4367